MedTrace Logo

Efficacy and Safety of RZL-012 on Submental Fat Reduction

NCT04867434 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 151

Last updated 2023-09-28

Study results available
· View outcomes & findings →

Summary

A total of 135 eligible male or female subjects will be randomized according to a predetermined randomization scheme (1:1:1 ratio) to receive a single multi-injection treatment of high dose RZL-012, low dose RZL-012, or placebo on Day 0. They will be monitored for safety and efficacy over 84 days.

Conditions

  • Submental Fat

Interventions

DRUG

RZL-012

small synthetic molecule for submental fat reduction

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Raziel Therapeutics Ltd.

    lead INDUSTRY

Principal Investigators

  • Raceli Gueta, PhD · Raziel Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-15
Primary Completion
2022-04-20
Completion
2022-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04867434 on ClinicalTrials.gov